Cargando…

Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS

Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotta, Sabna, Aldawsari, Hibah Mubarak, Badr-Eldin, Shaimaa M., Binmahfouz, Lenah S., Bakhaidar, Rana Bakur, Sreeharsha, Nagaraja, Nair, Anroop B., Ramnarayanan, Chandramouli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471313/
https://www.ncbi.nlm.nih.gov/pubmed/34575422
http://dx.doi.org/10.3390/pharmaceutics13091347
_version_ 1784574432385171456
author Kotta, Sabna
Aldawsari, Hibah Mubarak
Badr-Eldin, Shaimaa M.
Binmahfouz, Lenah S.
Bakhaidar, Rana Bakur
Sreeharsha, Nagaraja
Nair, Anroop B.
Ramnarayanan, Chandramouli
author_facet Kotta, Sabna
Aldawsari, Hibah Mubarak
Badr-Eldin, Shaimaa M.
Binmahfouz, Lenah S.
Bakhaidar, Rana Bakur
Sreeharsha, Nagaraja
Nair, Anroop B.
Ramnarayanan, Chandramouli
author_sort Kotta, Sabna
collection PubMed
description Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and accelerates tissue homeostasis towards disease resolution. To minimize non-target organ side effects arising from frequent and chronic use of dexamethasone, we designed biodegradable, lung-targeted microspheres with sustained release profiles. Dexamethasone-loaded lipopolymeric microspheres of PLGA (Poly Lactic-co-Glycolic Acid) and DPPC (Dipalmitoylphosphatidylcholine) stabilized with vitamin E TPGS (D-α-tocopheryl polyethylene glycol succinate) were prepared by a single emulsion technique that had a mean diameter of 8.83 ± 0.32 μm and were spherical in shape as revealed from electron microscopy imaging. Pharmacokinetic and biodistribution patterns studied in the lungs, liver, and spleen of Wistar rats showed high selectivity and targeting efficiency for the lung tissue (r(e) 13.98). As a proof-of-concept, in vivo efficacy of the microspheres was tested in the lipopolysaccharide-induced ARDS model in rats. Inflammation markers such as IL-1β, IL-6, and TNF-α, quantified in the bronchoalveolar lavage fluid indicated major improvement in rats treated with dexamethasone microspheres by intravenous route. Additionally, the microspheres substantially inhibited the protein infiltration, neutrophil accumulation and lipid peroxidation in the lungs of ARDS bearing rats, suggesting a reduction in oxidative stress. Histopathology showed decreased damage to the pulmonary tissue upon treatment with the dexamethasone-loaded microspheres. The multipronged formulation technology approach can thus serve as a potential treatment modality for reducing lung inflammation in ARDS. An improved therapeutic profile would help to reduce the dose, dosing frequency and, eventually, the toxicity.
format Online
Article
Text
id pubmed-8471313
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84713132021-09-27 Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS Kotta, Sabna Aldawsari, Hibah Mubarak Badr-Eldin, Shaimaa M. Binmahfouz, Lenah S. Bakhaidar, Rana Bakur Sreeharsha, Nagaraja Nair, Anroop B. Ramnarayanan, Chandramouli Pharmaceutics Article Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and accelerates tissue homeostasis towards disease resolution. To minimize non-target organ side effects arising from frequent and chronic use of dexamethasone, we designed biodegradable, lung-targeted microspheres with sustained release profiles. Dexamethasone-loaded lipopolymeric microspheres of PLGA (Poly Lactic-co-Glycolic Acid) and DPPC (Dipalmitoylphosphatidylcholine) stabilized with vitamin E TPGS (D-α-tocopheryl polyethylene glycol succinate) were prepared by a single emulsion technique that had a mean diameter of 8.83 ± 0.32 μm and were spherical in shape as revealed from electron microscopy imaging. Pharmacokinetic and biodistribution patterns studied in the lungs, liver, and spleen of Wistar rats showed high selectivity and targeting efficiency for the lung tissue (r(e) 13.98). As a proof-of-concept, in vivo efficacy of the microspheres was tested in the lipopolysaccharide-induced ARDS model in rats. Inflammation markers such as IL-1β, IL-6, and TNF-α, quantified in the bronchoalveolar lavage fluid indicated major improvement in rats treated with dexamethasone microspheres by intravenous route. Additionally, the microspheres substantially inhibited the protein infiltration, neutrophil accumulation and lipid peroxidation in the lungs of ARDS bearing rats, suggesting a reduction in oxidative stress. Histopathology showed decreased damage to the pulmonary tissue upon treatment with the dexamethasone-loaded microspheres. The multipronged formulation technology approach can thus serve as a potential treatment modality for reducing lung inflammation in ARDS. An improved therapeutic profile would help to reduce the dose, dosing frequency and, eventually, the toxicity. MDPI 2021-08-27 /pmc/articles/PMC8471313/ /pubmed/34575422 http://dx.doi.org/10.3390/pharmaceutics13091347 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kotta, Sabna
Aldawsari, Hibah Mubarak
Badr-Eldin, Shaimaa M.
Binmahfouz, Lenah S.
Bakhaidar, Rana Bakur
Sreeharsha, Nagaraja
Nair, Anroop B.
Ramnarayanan, Chandramouli
Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title_full Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title_fullStr Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title_full_unstemmed Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title_short Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
title_sort lung targeted lipopolymeric microspheres of dexamethasone for the treatment of ards
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471313/
https://www.ncbi.nlm.nih.gov/pubmed/34575422
http://dx.doi.org/10.3390/pharmaceutics13091347
work_keys_str_mv AT kottasabna lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT aldawsarihibahmubarak lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT badreldinshaimaam lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT binmahfouzlenahs lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT bakhaidarranabakur lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT sreeharshanagaraja lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT nairanroopb lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards
AT ramnarayananchandramouli lungtargetedlipopolymericmicrospheresofdexamethasoneforthetreatmentofards